Comment on

• Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease.

  Munyentwali H, Bouachi K, Audard V, Remy P, Lang P, Mojaat R, Deschênes G, Ronco PM, Plaisier EM, Dahan KY. Munyentwali H, et al. Kidney Int. 2013 Mar;83(3):511-6. doi: 10.1038/ki.2012.444. Epub 2013 Jan 16. Kidney Int. 2013. PMID: 23325085
• Could interleukin-17 be a therapeutic target of steroid-dependent minimal change disease?

  Eun Kim J, Il Shin J. Eun Kim J, et al. Kidney Int. 2013 Nov;84(5):1049. doi: 10.1038/ki.2013.323. Kidney Int. 2013. PMID: 24172738 No abstract available.